The rapid development of metagenomics,metabolomics,and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease(IBD).Multiple microorganisms play a role i...The rapid development of metagenomics,metabolomics,and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease(IBD).Multiple microorganisms play a role in intestinal health;these include bacteria,fungi,and viruses that exist in a dynamic balance to maintain mucosal homeostasis.Perturbations in the intestinal microbiota disrupt mucosal homeostasis and are closely related to IBD in humans and colitis in mice.Therefore,preventing or correcting the imbalance of microbiota may serve as a novel prevention or treatment strategy for IBD.We review the most recent evidence for direct or indirect interventions targeting intestinal microbiota for treatment of IBD in order to overcome the current limitations of IBD therapies and shed light on personalized treatment options.展开更多
基金Supported by National Natural Science Foundation of China,No.81273572 and No.81530096the Natural Science Foundation of Shanghai,No.17ZR1427800.
文摘The rapid development of metagenomics,metabolomics,and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease(IBD).Multiple microorganisms play a role in intestinal health;these include bacteria,fungi,and viruses that exist in a dynamic balance to maintain mucosal homeostasis.Perturbations in the intestinal microbiota disrupt mucosal homeostasis and are closely related to IBD in humans and colitis in mice.Therefore,preventing or correcting the imbalance of microbiota may serve as a novel prevention or treatment strategy for IBD.We review the most recent evidence for direct or indirect interventions targeting intestinal microbiota for treatment of IBD in order to overcome the current limitations of IBD therapies and shed light on personalized treatment options.
